Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Preliminary Efficacy of KNT-0916 in Subjects With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06800196 is registered in ClinicalTrials.gov with KinoTeck Therapeutics Co., Ltd as lead sponsor.

NCT NCT06800196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06800196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Preliminary Efficacy of KNT-0916 in Subjects With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Lead sponsor
KinoTeck Therapeutics Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2025
Completion date
December 31, 2027
Enrollment
151 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors with fgfr2 alterations, adult